U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H21FN2O
Molecular Weight 324.3919
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CITALOPRAM

SMILES

CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3

InChI

InChIKey=WSEQXVZVJXJVFP-UHFFFAOYSA-N
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H21FN2O
Molecular Weight 324.3919
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Citalopram (brand names: Celexa, Cipramil, and others) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has U.S. Food and Drug Administration approval to treat major depression,[2]which it received in 1998, and is prescribed off-label for other conditions. In Australia, the UK, Germany, Portugal, Poland, and most European countries, it is licensed for depressive episodes and panic disorder with or without agoraphobia. In Spain, it is also used for obsessive-compulsive disorder. Citalopram HBr is a racemic bicyclic phthalane derivative designated (±)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5carbonitrile, HBr. The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake. The single-and multiple-dose pharmacokinetics of citalopram are linear and dose-proportional in a dose range of 10-60 mg/day. Biotransformation of citalopram is mainly hepatic, with a mean terminal half-life of about 35 hours.

Originator

Sources: https://lakemedelsverket.se/LMF/Lakemedelsinformation/?nplid=19980626000180Bigler, Allan J., et al. 'Quantitative structure-activity-relationships in a series of selective 5-HT uptake inhibitors.' EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 12.3 (1977): 289-295.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.78 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CELEXA

Approved Use

Citalopram HBr is indicated for the treatment of depression. The efficacy of citalopram HBr in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the DSM-III and DSM-III-R category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The antidepressant action of citalopram HBr in hospitalized depressed patients has not been adequately studied. The efficacy of citalopram HBr in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo-controlled trials (see CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use citalopram HBr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Launch Date

1998
Primary
Celexa

Approved Use

INDICATIONS AND USAGE. Celexa (citalopram HBr) is indicated for the treatment of depression.

Launch Date

1998
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.2 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.5 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.1 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
21.7 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
43.7 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
65.6 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.6 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
204.5 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1153.2 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
843.7 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1010.4 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2070.3 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2946.5 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
533.2 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
77.5 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79.3 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
38.5 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
40 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
39.5 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
36.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
26%
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
26%
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
26%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
800 mg single, oral
Overdose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Other AEs: Dizziness, Drowsiness...
Other AEs:
Dizziness (mild, 1 patient)
Drowsiness (mild, 1 patient)
Sources:
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Disc. AE: Asthenia, Nausea...
AEs leading to
discontinuation/dose reduction:
Asthenia (1%)
Nausea (4%)
Dry mouth (1%)
Vomiting (1%)
Dizziness (2%)
Insomnia (3%)
Somnolence (2%)
Agitation (1%)
Sources:
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Other AEs: Seizures, Tachycardia...
Other AEs:
Seizures (1 patient)
Tachycardia (1 patient)
Neuromuscular disorders NEC (1 patient)
Hyperthermia (severe, 1 patient)
Sources:
360 mg 1 times / day multiple, oral
Highest studied dose
Dose: 360 mg, 1 times / day
Route: oral
Route: multiple
Dose: 360 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Other AEs: Dizziness, Sweating...
Other AEs:
Dizziness (grade 5)
Sweating
Nausea
Vomiting
Tremor
Somnolence
Sinus tachycardia
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness mild, 1 patient
800 mg single, oral
Overdose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Drowsiness mild, 1 patient
800 mg single, oral
Overdose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Agitation 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Asthenia 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Dry mouth 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Vomiting 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Dizziness 2%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Somnolence 2%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Insomnia 3%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Nausea 4%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Neuromuscular disorders NEC 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Seizures 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Tachycardia 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Hyperthermia severe, 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Nausea
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Sinus tachycardia
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Somnolence
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Sweating
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Tremor
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Vomiting
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Dizziness grade 5
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation.
1999
Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram.
1999 Aug
Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
1999 Dec
[Citalopram in forensic samples. Citalopram concentrations in samples from legal autopsies and from living persons in connection with traffic accidents or cases of violence in Denmark 1989-1996].
1999 Jul 26
Citalopram and sexual side effects of selective serotonin reuptake inhibitors.
1999 May
Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection.
1999 Nov 12
Antidepressant drugs appear to enhance cocaine-induced toxicity.
2000 Feb
Citalopram and breast-feeding: serum concentration and side effects in the infant.
2000 Jan 15
Low serum sodium concentrations during treatment with citalopram in elderly patients: relationship to serum citalopram levels and to platelet serotonin 5-HT2A receptor status.
2000 Oct
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
2001
Clinical significance of monitoring early symptom change to predict outcome.
2001
Evidence of early onset of antidepressant effect in randomized controlled trials.
2001
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
2001
Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.
2001 Apr
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.
2001 Apr
Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care.
2001 Apr
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
2001 Aug
Relationship between central serotonergic neurotransmission and reduction in alcohol intake by citalopram.
2001 Aug 1
Some behavioural effects of antidepressant drugs are time-dependent.
2001 Feb
Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management.
2001 Feb
Disinhibition of libido: an adverse effect of SSRI?
2001 Feb
Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram.
2001 Feb
Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram.
2001 Feb
Citalopram-induced bruxism.
2001 Feb
Female sexual dysfunction and antidepressant use.
2001 Feb
Evidence for a serotonin transporter deficit in experimental acute liver failure.
2001 Feb
[Depression and anxiety in the elderly still underdiagnosed. SSRI preparations in conjunction with psychotherapy provide effective treatment].
2001 Feb 21
Too much hypothalamic serotonin transporter is bad for your mood.
2001 Jan
[Depressive disorders in neurologic rehabilitation: therapy with paroxetine].
2001 Jan
Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study.
2001 Jan
Does interaction between zinc and glutamate system play a significant role in the mechanism of antidepressant action?
2001 Jan-Feb
Citalopram in refractory obsessive-compulsive disorder: an open study.
2001 Jul
Involvement of adenosine in the effect of antidepressants on glutamate and aspartate release in the rat prefrontal cortex.
2001 Jun
The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study.
2001 Jun
Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study.
2001 Mar
Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice.
2001 Mar
Lack of citalopram effect on oral digoxin pharmacokinetics.
2001 Mar
Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala.
2001 Mar
Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition.
2001 Mar
Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.
2001 Mar
Functional consequences of 5-HT transporter gene disruption on 5-HT(1a) receptor-mediated regulation of dorsal raphe and hippocampal cell activity.
2001 Mar 15
Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.
2001 May
Alzheimer's disease and related disorders.
2001 May
Rapid response to low dose citalopram in pathological crying.
2001 May-Jun
Trichotillomania associated with dementia: a case report.
2001 May-Jun
Citalopram-induced dyskinesia of the tongue: a video presentation.
2016 Dec 23
Patents

Sample Use Guides

Initial Treatment Celexa (citalopram HBr) should be administered at an initial dose of 20 mg once daily, with an increase to a maximum dose of 40 mg/day at an interval of no less than one week. Doses above 40 mg/day are not recommended due to the risk of QT prolongation. Additionally, the only study pertinent to dose response for effectiveness did not demonstrate an advantage for the 60 mg/day dose over the 40 mg/day dose. Special Populations 20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor.
Route of Administration: Oral
It was investigated the mechanisms of cytotoxic effects of in vitro and in vivo citalopram treatment on liver and the following cytolethal events. For in vitro experiments, freshly isolated rat hepatocytes were exposed to citalopram along with/without various agents. In the in vitro experiments, citalopram (500 µM) exposure demonstrated cell death, a marked elevation in ROS formation, mitochondrial potential collapse, lysosomal membrane leakiness, glutathione (GSH) depletion and lipid peroxidation. In vivo biochemistry panel assays for liver enzymes function (AST, ALT and GGTP) and histological examination confirmed citalopram (20 mg/kg)-induced damage. Citalopram-induced oxidative stress cytotoxicity markers were significantly prevented by antioxidants, ROS scavengers, MPT pore sealing agents, endocytosis inhibitors, ATP generators and CYP inhibitors.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:29:53 GMT 2023
Edited
by admin
on Fri Dec 15 16:29:53 GMT 2023
Record UNII
0DHU5B8D6V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CITALOPRAM
INN   MART.   MI   USP   VANDF   WHO-DD  
INN  
Official Name English
CITALOPRAM [MI]
Common Name English
Citalopram [WHO-DD]
Common Name English
CITALOPRAM [MART.]
Common Name English
CITALOPRAM [VANDF]
Common Name English
CITADUR
Brand Name English
citalopram [INN]
Common Name English
CITALOPRAM [USP IMPURITY]
Common Name English
1-(3-(DIMETHYLAMINO)PROPYL)-1-(P-FLUOROPHENYL)-5-PHTHALANCARBONITRILE
Common Name English
Classification Tree Code System Code
LIVERTOX 212
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
NCI_THESAURUS C265
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
NCI_THESAURUS C94725
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
WHO-VATC QN06AB04
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
NDF-RT N0000175696
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
WHO-ATC N06AB04
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
NDF-RT N0000000109
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
Code System Code Type Description
LACTMED
Citalopram
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
ECHA (EC/EINECS)
261-891-1
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
INN
4138
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
CAS
59729-33-8
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
RXCUI
2556
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
CITALOPRAM
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
CHEBI
3723
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
DRUG CENTRAL
663
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
PUBCHEM
2771
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
DAILYMED
0DHU5B8D6V
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
EVMPD
SUB07485MIG
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
MESH
D015283
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
SMS_ID
100000091311
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID8022826
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
MERCK INDEX
m3587
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C61680
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
FDA UNII
0DHU5B8D6V
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
ChEMBL
CHEMBL549
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
IUPHAR
7547
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
DRUG BANK
DB00215
Created by admin on Fri Dec 15 16:29:54 GMT 2023 , Edited by admin on Fri Dec 15 16:29:54 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
in vitro ER in the MDCK-MDR1 cell line from National Institutes of Health. Weak substrate in-vivo.
EFFLUX RATIO
TARGET -> INHIBITOR
BINDING
IC50
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC